Dosimetry of [

177Lu PSMA dosimetry metaanalysis prostate cancer theranostics

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
03 Jul 2024
Historique:
received: 16 01 2024
accepted: 29 04 2024
medline: 4 7 2024
pubmed: 4 7 2024
entrez: 3 7 2024
Statut: aheadofprint

Résumé

Novel theranostic approaches using radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged for treating metastatic castration-resistant prostate cancer. The physical properties and commercial availability of

Identifiants

DOI: 10.2967/jnumed.124.267452 PMID: 38960712
pubmed: 38960712
pii: jnumed.124.267452
doi: 10.2967/jnumed.124.267452
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Zachary Ells (Z)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; and.

Tristan R Grogan (TR)

Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California.

Johannes Czernin (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; and.

Magnus Dahlbom (M)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; and.

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; and jcalais@mednet.ucla.edu.

Classifications MeSH